NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
Boston, MA
